RCKT ROCKET PHARMACEUTICALS INC Legal Disputes 8-K Filing 2025 - Regulatory Compliance On May 27, 2025, Rocket Pharmaceuticals, Inc. announced that the FDA placed its Phase 2 clinical trial of RP-A501 for Danon disease on clinical hold. This development raises regulatory concerns for the company's ongoing research.Get access to all SEC 8-K filings of the ROCKET PHARMACEUTICALS INC